Tags

Type your tag names separated by a space and hit enter

Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
Nutr Metab Cardiovasc Dis. 2001 Feb; 11(1):7-16.NM

Abstract

BACKGROUND AND AIM

The aim of the present study was to see whether a moderate dose of omega-3 fatty acids (FA) potentiates the beneficial effects of statins on the high risk for coronary heart disease (CHD) in patients with combined hyperlipemia.

METHODS AND RESULTS

In the present double-blind parallel study, 42 patients with combined hyperlipemia with serum triglycerides 2-15 mmol/L-1 and serum total cholesterol > 5.3 mmol/L-1 at the end of a three-month dietary run-in period were treated with 10 mg/d atorvastatin for 10 or more weeks. During the last 5 weeks they were randomized into two groups that received either 1.68 g/d omega-3 FA as ethylesters of eicosapentaenoic (45%) and docosahexaenoic acids (39%), or placebo (corn oil). As expected, atorvastatin significantly reduced serum total LDL-cholesterol (LDL-C), triglycerides and apolipoproteins B, E, CII and CIII, whereas HDL-cholesterol (HDL-C) was increased. Addition of omega-3 FA further increased HDL-C (p < 0.03), and reduced systolic blood pressure (< 0.03), while the small dense LDL-particles (LDL III) (p < 0.05) and postprandial hypertriglyceridemia (p < 0.01) were reduced compared with the baseline, though there were no significant differences to the placebo group. This may be related to the large individual variation in these parameters and the small number of patients. No significant effects on basic or postheparin activities of lipoprotein lipase or hepatic lipase were observed after atorvastatin with or without addition of omega-3 FA.

CONCLUSIONS

This study indicates that addition of a low dose of omega-3 FA may further improve the risk profile for CHD in patients with combined hyperlipemia treated with atorvastatin. The effect is related to reduction of postprandial hyperlipemia and redistribution of LDL subfractions.

Authors+Show Affiliations

Department of Medicine, Institute of Clinical Medicine, University of Tromsø, Norway.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11383326

Citation

Nordøy, A, et al. "Effects of Atorvastatin and Omega-3 Fatty Acids On LDL Subfractions and Postprandial Hyperlipemia in Patients With Combined Hyperlipemia." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 11, no. 1, 2001, pp. 7-16.
Nordøy A, Hansen JB, Brox J, et al. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis. 2001;11(1):7-16.
Nordøy, A., Hansen, J. B., Brox, J., & Svensson, B. (2001). Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 11(1), 7-16.
Nordøy A, et al. Effects of Atorvastatin and Omega-3 Fatty Acids On LDL Subfractions and Postprandial Hyperlipemia in Patients With Combined Hyperlipemia. Nutr Metab Cardiovasc Dis. 2001;11(1):7-16. PubMed PMID: 11383326.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. AU - Nordøy,A, AU - Hansen,J B, AU - Brox,J, AU - Svensson,B, PY - 2001/6/1/pubmed PY - 2002/1/23/medline PY - 2001/6/1/entrez SP - 7 EP - 16 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 11 IS - 1 N2 - BACKGROUND AND AIM: The aim of the present study was to see whether a moderate dose of omega-3 fatty acids (FA) potentiates the beneficial effects of statins on the high risk for coronary heart disease (CHD) in patients with combined hyperlipemia. METHODS AND RESULTS: In the present double-blind parallel study, 42 patients with combined hyperlipemia with serum triglycerides 2-15 mmol/L-1 and serum total cholesterol > 5.3 mmol/L-1 at the end of a three-month dietary run-in period were treated with 10 mg/d atorvastatin for 10 or more weeks. During the last 5 weeks they were randomized into two groups that received either 1.68 g/d omega-3 FA as ethylesters of eicosapentaenoic (45%) and docosahexaenoic acids (39%), or placebo (corn oil). As expected, atorvastatin significantly reduced serum total LDL-cholesterol (LDL-C), triglycerides and apolipoproteins B, E, CII and CIII, whereas HDL-cholesterol (HDL-C) was increased. Addition of omega-3 FA further increased HDL-C (p < 0.03), and reduced systolic blood pressure (< 0.03), while the small dense LDL-particles (LDL III) (p < 0.05) and postprandial hypertriglyceridemia (p < 0.01) were reduced compared with the baseline, though there were no significant differences to the placebo group. This may be related to the large individual variation in these parameters and the small number of patients. No significant effects on basic or postheparin activities of lipoprotein lipase or hepatic lipase were observed after atorvastatin with or without addition of omega-3 FA. CONCLUSIONS: This study indicates that addition of a low dose of omega-3 FA may further improve the risk profile for CHD in patients with combined hyperlipemia treated with atorvastatin. The effect is related to reduction of postprandial hyperlipemia and redistribution of LDL subfractions. SN - 0939-4753 UR - https://www.unboundmedicine.com/medline/citation/11383326/Effects_of_atorvastatin_and_omega_3_fatty_acids_on_LDL_subfractions_and_postprandial_hyperlipemia_in_patients_with_combined_hyperlipemia_ L2 - https://medlineplus.gov/ldlthebadcholesterol.html DB - PRIME DP - Unbound Medicine ER -